GlassScriptPhysician profile
Meihong Li
NPI 1407935356
$2,345.39
in general payments reported to CMS, 2019-2025
24 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $171 · 2021: $98.51 · 2022: $96.41 · 2023: $341 · 2024: $538 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,206.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $329.03 | 2019-2023 | |
| Novo Nordisk INC | $294.83 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $294.35 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $277.79 | 2019-2025 | Breztri, Airsupra |
| Exact Sciences Corporation | $259.17 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $188.47 | 2019-2025 | Arexvy, Shingrix |
| Pfizer INC. | $126.60 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $98.98 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Amarin Pharma, INC. | $95.10 | 2019-2020 | |
| Genentech USA, INC. | $54.00 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $42.90 | 2024-2025 | Voquezna |
| Abbvie INC. | $39.16 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $28.03 | 2019 | |
| Allergan, INC. | $27.58 | 2019 | |
| Amgen INC. | $27.04 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $26.26 | 2019 | |
| Hikma Pharmaceuticals USA | $25.60 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.65 | 2019 | |
| Astellas Pharma US INC | $16.65 | 2024 | Veozah |
| Eisai INC. | $15.35 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.66 | 2019 | |
| Azurity Pharmaceuticals, INC. | $14.07 | 2024 | Edarbi |
| Novartis Pharmaceuticals Corporation | $13.54 | 2019 | |
| Seqirus USA INC | $11.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meihong Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.